{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:12:57Z","timestamp":1789693977235,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09476"],"award-info":[{"award-number":["19K09476"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Brain Tumor Pathol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10014-021-00407-0","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T14:02:37Z","timestamp":1625320957000},"page":"228-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-8323","authenticated-orcid":false,"given":"Manabu","family":"Natsumeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramil","family":"Gabdulkhaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kanemaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayasu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichirou","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisa C.","family":"Schreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,3]]},"reference":[{"key":"407_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397\u2013405","journal-title":"Acta Neuropathol"},{"key":"407_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13000-016-0506-2","volume":"11","author":"F Behling","year":"2016","unstructured":"Behling F, Barrantes-Freer A, Skardelly M et al (2016) Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol 11:55","journal-title":"Diagn Pathol"},{"key":"407_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/cancers11091262","volume":"11","author":"KC Schreck","year":"2019","unstructured":"Schreck KC, Grossman SA, Pratilas CA (2019) BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers (Basel) 11:1262","journal-title":"Cancers (Basel)"},{"key":"407_CR4","doi-asserted-by":"publisher","first-page":"e17948","DOI":"10.1371\/journal.pone.0017948","volume":"6","author":"D Dias-Santagata","year":"2011","unstructured":"Dias-Santagata D, Lam Q, Vernovsky K et al (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE 6:e17948","journal-title":"PLoS ONE"},{"key":"407_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462\u2013477","journal-title":"Cell"},{"key":"407_CR6","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.18632\/oncotarget.5456","volume":"7","author":"R Zhang","year":"2016","unstructured":"Zhang R, Shi Z, Chen H et al (2016) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7:5030\u20135041","journal-title":"Oncotarget"},{"key":"407_CR7","doi-asserted-by":"crossref","unstructured":"Schreck KC, Vera E, Aboud O et al (2018) The natural history of braf V600E-mutated glioblastomas in adults. In: SNO Annual Meeting 2018, vol 20. New Orleans, pp i164","DOI":"10.1093\/neuonc\/noy148.684"},{"key":"407_CR8","volume-title":"WHO classification of tumours of the central nervous system","author":"DN Louis","year":"2016","unstructured":"Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system. IARC, Lyon"},{"key":"407_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40478-019-0774-7","volume":"7","author":"Y Kanemaru","year":"2019","unstructured":"Kanemaru Y, Natsumeda M, Okada M et al (2019) Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathol Commun 7:119","journal-title":"Acta Neuropathol Commun"},{"key":"407_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.6004\/jnccn.2017.7052","volume":"16","author":"KC Schreck","year":"2018","unstructured":"Schreck KC, Guajardo A, Lin DDM et al (2018) Concurrent BRAF\/MEK inhibitors in BRAF V600-mutant high-grade primary brain tumors. J Natl Compr Canc Netw 16:343\u2013347","journal-title":"J Natl Compr Canc Netw"},{"key":"407_CR11","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley T, Touat M, Subbiah V et al (2018) BRAF inhibition in BRAFV600-mutant gliomas\u2014results from the VE-BASKET study. J Clin Oncol 36:3477\u20133484","journal-title":"J Clin Oncol"},{"key":"407_CR12","doi-asserted-by":"crossref","unstructured":"Subbiah V, Stein A, van den Bent M (2021) ROR: dabrafenib plus trametinib in BRAF V600E\u2013mutant high-grade and low-grade glioblastoma. In: AACR Annual Meeting 2021. Virtual","DOI":"10.1158\/1538-7445.AM2021-CT025"},{"key":"407_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/PAT.0000000000000119","volume":"46","author":"K Dvorak","year":"2014","unstructured":"Dvorak K, Aggeler B, Palting J et al (2014) Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Pathology 46:509\u2013517","journal-title":"Pathology"},{"key":"407_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/cancers11060742","volume":"11","author":"M Takeda","year":"2019","unstructured":"Takeda M, Sakai K, Takahama T et al (2019) New era for next-generation sequencing in Japan. Cancers (Basel) 11:742","journal-title":"Cancers (Basel)"},{"key":"407_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-021-03719-5","volume":"152","author":"MJ Lim-Fat","year":"2021","unstructured":"Lim-Fat MJ, Song KW, Iorgulescu JB et al (2021) Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol 152:515\u2013522","journal-title":"J Neurooncol"},{"key":"407_CR16","doi-asserted-by":"crossref","unstructured":"Stence N, Mulcahy-Levy J, Hoffman L et al (2018) Imaging characteristics of braf V600E mutated pediatric brain tumors. In: SNO Annual Meeting 2018, vol 20. New Orleans, pp i174","DOI":"10.1093\/neuonc\/noy059.661"},{"key":"407_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3171\/2011.5.JNS11128","volume":"115","author":"G Kaur","year":"2011","unstructured":"Kaur G, Bloch O, Jian BJ et al (2011) A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg 115:754\u2013759","journal-title":"J Neurosurg"},{"key":"407_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37:569-583 e565","journal-title":"Cancer Cell"},{"key":"407_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1593\/tlo.12328","volume":"5","author":"JK Myung","year":"2012","unstructured":"Myung JK, Cho H, Park CK et al (2012) Analysis of BRAFV600E mutation in central nervous system tumors. Transl Oncol 5:430\u2013436","journal-title":"Transl Oncol"},{"key":"407_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.18632\/oncotarget.26560","volume":"10","author":"SA Toll","year":"2019","unstructured":"Toll SA, Tran HN, Cotter J et al (2019) Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget 10:551\u2013557","journal-title":"Oncotarget"},{"key":"407_CR21","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.18632\/oncotarget.26932","volume":"10","author":"PYM Woo","year":"2019","unstructured":"Woo PYM, Lam TC, Pu JKS et al (2019) Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. Oncotarget 10:3818\u20133826","journal-title":"Oncotarget"},{"key":"407_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","volume":"16","author":"TM Johanns","year":"2018","unstructured":"Johanns TM, Ferguson CJ, Grierson PM et al (2018) Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw 16:4\u201310","journal-title":"J Natl Compr Canc Netw"},{"key":"407_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-DeMasters","year":"2013","unstructured":"Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37:685\u2013698","journal-title":"Am J Surg Pathol"},{"key":"407_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3174\/ajnr.A3253","volume":"34","author":"BM Ellingson","year":"2013","unstructured":"Ellingson BM, Lai A, Harris RJ et al (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34:533\u2013540","journal-title":"AJNR Am J Neuroradiol"},{"key":"407_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10143-017-0899-8","volume":"41","author":"R Altieri","year":"2018","unstructured":"Altieri R, Zenga F, Ducati A et al (2018) Tumor location and patient age predict biological signatures of high-grade gliomas. Neurosurg Rev 41:599\u2013604","journal-title":"Neurosurg Rev"},{"key":"407_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.humpath.2013.08.024","volume":"45","author":"SJ Byeon","year":"2014","unstructured":"Byeon SJ, Cho HJ, Baek HW et al (2014) Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol 45:611\u2013620","journal-title":"Hum Pathol"},{"key":"407_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/bpa.12572","volume":"28","author":"N Nakajima","year":"2018","unstructured":"Nakajima N, Nobusawa S, Nakata S et al (2018) BRAF V600E, TERT promoter mutations and CDKN2A\/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol 28:663\u2013673","journal-title":"Brain Pathol"}],"container-title":["Brain Tumor Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-021-00407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10014-021-00407-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10014-021-00407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T03:35:50Z","timestamp":1627443350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10014-021-00407-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s10014-021-00407-0","relation":{},"ISSN":["1433-7398","1861-387X"],"issn-type":[{"value":"1433-7398","type":"print"},{"value":"1861-387X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"13 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review boards at Niigata University (IRB2020-0491) and Johns Hopkins School of Medicine (IRB00243637) in accordance with the Declaration of Helsinki. The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics standards"}}]}}